Novo Nordisk Halts Two More Heart Failure Trials of Ziltivekimab After a Data Committee Found Futility

Hopes for promising heart drug crushed as clinical trial fails

Cardiologists are reeling after an experimental drug failed a massive clinical trial, upending hopes for a new era of heart disease care.

Novo Nordisk faces fresh setback as it halts two heart drug trials

Novo Nordisk halts two late-stage ziltivekimab heart drug trials, deepening pipeline setbacks for NVO investors.

Novo Nordisk Halts Two More Heart Failure Trials of Ziltivekimab After a Data Committee Found Futility

Novo Nordisk stopped the HERMES and ATHENA heart failure trials of ziltivekimab for futility, ending study treatment for enrolled patients.

Novo scraps two more heart drug trials, further dimming ...

Novo Nordisk's IL-6 drug flunks two more heart trials

Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.